> Detailanzeige

Verderese, John Paul; Stepanova, Maria; Lam, Brian; Racila, Andrei; Kolacevski, Andrej; Allen, David; Hodson, Erin; Aslani-Amoli, Bahareh; Homeyer, Michael; Stanmyre, Sarah; Stevens, Helen; Garofalo, Stephanie; Henry, Linda; Venkatesan, Chapy; Gerber, Lynn H; Motew, Steve J; Jones, J Stephen; Younossi, Zobair M

Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience
  • Beteiligte: Verderese, John Paul; Stepanova, Maria; Lam, Brian; Racila, Andrei; Kolacevski, Andrej; Allen, David; Hodson, Erin; Aslani-Amoli, Bahareh; Homeyer, Michael; Stanmyre, Sarah; Stevens, Helen; Garofalo, Stephanie; Henry, Linda; Venkatesan, Chapy; Gerber, Lynn H; Motew, Steve J; Jones, J Stephen; Younossi, Zobair M
  • Erschienen: Oxford University Press (OUP), 2022
  • Erschienen in: Clinical Infectious Diseases
  • Sprache: Englisch
  • DOI: 10.1093/cid/ciab579
  • ISSN: 1058-4838; 1537-6591
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Neutralizing monoclonal antibody (NmAb) treatments have received Emergency Use Authorization to treat patients with mild or moderate COVID-19 infection. To date, no real- world data on the efficacy of NmAbs have been reported from clinical practice. We assessed the impact of NmAb treatment given in the outpatient clinical practice setting on hospital utilization.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Electronic medical records were used to identify adult COVID-19 patients who received NmAbs (bamlanivimab [BAM] or casirivimab and imdevimab [REGN-COV2]) and historic COVID-19 controls. Post-index hospitalization rates were compared.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>707 confirmed COVID-19 patients received NmAbs and 1709 historic COVID-19 controls were included; 553 (78%) received BAM, 154 (22%) received REGN-COV2. Patients receiving NmAb infusion had significantly lower hospitalization rates (5.8% vs 11.4%, P &amp;lt; .0001), shorter length of stay if hospitalized (mean, 5.2 vs 7.4 days; P = .02), and fewer ED visits within 30 days post-index (8.1% vs 12.3%, P = .003) than controls. Hospitalization-free survival was significantly longer in NmAb patients compared with controls (P &amp;lt; .0001). There was a trend towards a lower hospitalization rate among patients who received NmAbs within 2–4 days after symptom onset. In multivariate analysis, having received an NmAb transfusion was independently associated with a lower risk of hospitalization after adjustment for age, sex, race, BMI, and referral source (adjusted HR [95% CI], .54 [0.38–0.79]; P = .0012). Overall mortality was not different between the 2 groups.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>NmAb treatment reduced hospital utilization, especially when received within a few days of symptom onset. Further study is needed to validate these findings.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang